Eledon Pharmaceuticals Net Income
| ELDN Stock | USD 2.13 0.06 2.74% |
As of the 10th of February, Eledon Pharmaceuticals shows the Variance of 61.7, standard deviation of 7.86, and Mean Deviation of 4.5. Eledon Pharmaceuticals technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Eledon Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Eledon Pharmaceuticals' valuation are provided below:We have found one hundred twenty available fundamental signals for Eledon Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to verify Eledon Pharmaceuticals' prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 10th of February 2026, Enterprise Value is likely to grow to about 217.8 M, while Market Cap is likely to drop about 130.4 M. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -32.6 M | -34.2 M | |
| Net Loss | -31.1 M | -29.5 M | |
| Net Loss | -32.6 M | -34.2 M | |
| Net Loss | (0.67) | (0.70) | |
| Net Income Per E B T | 0.91 | 0.78 |
Eledon | Net Income | Build AI portfolio with Eledon Stock |
Evaluating Eledon Pharmaceuticals's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Eledon Pharmaceuticals's fundamental strength.
Latest Eledon Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Eledon Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Eledon Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Eledon Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Eledon Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eledon Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (36.18 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Eledon Net Income Regression Statistics
| Arithmetic Mean | (28,397,558) | |
| Coefficient Of Variation | (68.61) | |
| Mean Deviation | 14,306,708 | |
| Median | (23,296,000) | |
| Standard Deviation | 19,484,428 | |
| Sample Variance | 379.6T | |
| Range | 78.3M | |
| R-Value | (0.53) | |
| Mean Square Error | 290.1T | |
| R-Squared | 0.28 | |
| Significance | 0.03 | |
| Slope | (2,055,211) | |
| Total Sum of Squares | 6074.3T |
Eledon Net Income History
Other Fundumenentals of Eledon Pharmaceuticals
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Eledon Pharmaceuticals Net Income component correlations
Eledon Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Eledon Pharmaceuticals is extremely important. It helps to project a fair market value of Eledon Stock properly, considering its historical fundamentals such as Net Income. Since Eledon Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eledon Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eledon Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Eledon diversify its offerings? Factors like these will boost the valuation of Eledon Pharmaceuticals. Projected growth potential of Eledon fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Eledon Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Eledon Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Eledon's accounting equity. The concept of intrinsic value - what Eledon Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Eledon Pharmaceuticals' price substantially above or below its fundamental value.
It's important to distinguish between Eledon Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Eledon Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Eledon Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Eledon Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Eledon Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Eledon Pharmaceuticals.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Eledon Pharmaceuticals on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Eledon Pharmaceuticals or generate 0.0% return on investment in Eledon Pharmaceuticals over 90 days. Eledon Pharmaceuticals is related to or competes with Puma Biotechnology, Abeona Therapeutics, Allogene Therapeutics, Vanda Pharmaceuticals, Atea Pharmaceuticals, Voyager Therapeutics, and Entrada Therapeutics. Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients... More
Eledon Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Eledon Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Eledon Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 51.49 | |||
| Value At Risk | (8.37) | |||
| Potential Upside | 9.22 |
Eledon Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Eledon Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Eledon Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Eledon Pharmaceuticals historical prices to predict the future Eledon Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.84) | |||
| Total Risk Alpha | (1.48) | |||
| Treynor Ratio | (0.24) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Eledon Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Eledon Pharmaceuticals February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.23) | |||
| Mean Deviation | 4.5 | |||
| Coefficient Of Variation | (1,293) | |||
| Standard Deviation | 7.86 | |||
| Variance | 61.7 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.84) | |||
| Total Risk Alpha | (1.48) | |||
| Treynor Ratio | (0.24) | |||
| Maximum Drawdown | 51.49 | |||
| Value At Risk | (8.37) | |||
| Potential Upside | 9.22 | |||
| Skewness | (3.74) | |||
| Kurtosis | 23.27 |
Eledon Pharmaceuticals Backtested Returns
Eledon Pharmaceuticals appears to be risky, given 3 months investment horizon. Eledon Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.0654, which denotes the company had a 0.0654 % return per unit of risk over the last 3 months. We have found twenty-two technical indicators for Eledon Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please utilize Eledon Pharmaceuticals' Variance of 61.7, standard deviation of 7.86, and Mean Deviation of 4.5 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Eledon Pharmaceuticals holds a performance score of 5. The firm shows a Beta (market volatility) of 2.53, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Eledon Pharmaceuticals will likely underperform. Please check Eledon Pharmaceuticals' potential upside, and the relationship between the jensen alpha and daily balance of power , to make a quick decision on whether Eledon Pharmaceuticals' price patterns will revert.
Auto-correlation | -0.21 |
Weak reverse predictability
Eledon Pharmaceuticals has weak reverse predictability. Overlapping area represents the amount of predictability between Eledon Pharmaceuticals time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Eledon Pharmaceuticals price movement. The serial correlation of -0.21 indicates that over 21.0% of current Eledon Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.21 | |
| Spearman Rank Test | -0.01 | |
| Residual Average | 0.0 | |
| Price Variance | 0.06 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Eledon Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Eledon Pharmaceuticals reported net income of (36.18 Million). This is 110.6% lower than that of the Biotechnology sector and 151.66% lower than that of the Health Care industry. The net income for all United States stocks is 106.34% higher than that of the company.
Eledon Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eledon Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eledon Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eledon Pharmaceuticals by comparing valuation metrics of similar companies.Eledon Pharmaceuticals is currently under evaluation in net income category among its peers.
Eledon Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Eledon Pharmaceuticals from analyzing Eledon Pharmaceuticals' financial statements. These drivers represent accounts that assess Eledon Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Eledon Pharmaceuticals' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 65.4M | 32.6M | 44.3M | 200.0M | 230.0M | 130.4M | |
| Enterprise Value | (18.7M) | (23.1M) | 40.1M | 180.4M | 207.5M | 217.8M |
Eledon Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Eledon Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Eledon Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Eledon Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Eledon Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Eledon Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Eledon Pharmaceuticals' value.| Shares | Awm Investment Company Inc | 2025-06-30 | 1.1 M | Susquehanna International Group, Llp | 2025-06-30 | 1 M | Ikarian Capital, Llc | 2025-06-30 | 1 M | Schonfeld Strategic Advisors Llc | 2025-06-30 | 998.5 K | Zimmer Partners Lp | 2025-06-30 | 980.7 K | Alyeska Investment Group, L.p. | 2025-06-30 | 933.5 K | Sanofi | 2025-06-30 | 815 K | Siren, L.l.c. | 2025-06-30 | 690.2 K | 22nw, Lp | 2025-06-30 | 636.4 K | Bvf Inc | 2025-06-30 | 6.3 M | Ra Capital Management, Llc | 2025-06-30 | 3.6 M |
Eledon Fundamentals
| Return On Equity | -0.95 | ||||
| Return On Asset | -0.44 | ||||
| Current Valuation | 81.31 M | ||||
| Shares Outstanding | 79.63 M | ||||
| Shares Owned By Insiders | 1.08 % | ||||
| Shares Owned By Institutions | 56.90 % | ||||
| Number Of Shares Shorted | 6.32 M | ||||
| Price To Book | 4.92 X | ||||
| EBITDA | (35.39 M) | ||||
| Net Income | (36.18 M) | ||||
| Cash And Equivalents | 70.46 M | ||||
| Cash Per Share | 5.12 X | ||||
| Total Debt | 954 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 22.22 X | ||||
| Book Value Per Share | 1.52 X | ||||
| Cash Flow From Operations | (47.27 M) | ||||
| Short Ratio | 7.14 X | ||||
| Earnings Per Share | (1.30) X | ||||
| Price To Earnings To Growth | 0.01 X | ||||
| Target Price | 8.0 | ||||
| Number Of Employees | 31 | ||||
| Beta | 0.89 | ||||
| Market Capitalization | 174.39 M | ||||
| Total Asset | 177.41 M | ||||
| Retained Earnings | (355.59 M) | ||||
| Working Capital | 132.15 M | ||||
| Net Asset | 177.41 M |
About Eledon Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eledon Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eledon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eledon Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Eledon Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eledon Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eledon Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Eledon Stock
The ability to find closely correlated positions to Eledon Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eledon Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eledon Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eledon Pharmaceuticals to buy it.
The correlation of Eledon Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eledon Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eledon Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eledon Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Will Biotechnology sector continue expanding? Could Eledon diversify its offerings? Factors like these will boost the valuation of Eledon Pharmaceuticals. Projected growth potential of Eledon fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Eledon Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Eledon Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Eledon's accounting equity. The concept of intrinsic value - what Eledon Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Eledon Pharmaceuticals' price substantially above or below its fundamental value.
It's important to distinguish between Eledon Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Eledon Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Eledon Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.